Zhang Hui, Yuan Jin, Xiang Yuehua, Liu Yong
Department of Pulmonary and Critical Care Medicine, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China.
Department of Pulmonary Disease Diabetes Mellitus, The National Hospital of Enshi Autonomous Prefecture, Enshi, China.
J Oncol. 2022 Oct 15;2022:2099327. doi: 10.1155/2022/2099327. eCollection 2022.
The incidence of lung adenocarcinoma (LUAD), the most common subtype of lung cancer, continues to make lung cancer the largest cause of cancer-related deaths worldwide. Long noncoding RNAs (lncRNAs) have been shown to have a significant role in both the onset and progression of lung cancer. In this study, we aimed to investigate the clinical significance and underlying mechanism of lncRNA NPSR1-AS1 (NPSR1-AS1) in LUAD. First, we performed an analysis on TCGA and identified 229 differentially expressed lncRNAs (DELs) (including 216 upregulated lncRNAs and 13 downregulated lncRNAs). Then, we carried out a screening of the lncRNAs associated with survival, and a total of 382 survival-related lncRNAs were found. 15 survival-related DELs were identified. Among them, our attention focused on NPSR1-AS1. We found that the expression of NPSR1-AS1 was much higher in LUAD specimens compared to nontumor tissues. According to the results of the ROC assays, high NPSR1-AS1 expression had an AUC value of 0.904 for LUAD, with a 95% confidence interval ranging from 0.881 to 0.927. The expression of NPSR1-AS1 was shown to be significantly elevated in a wide variety of cancers, according to the findings of a pancancer investigation. Functional enrichment analysis confirmed that NPSR1-AS1 was involved in LUAD progression via regulating several tumor-related pathways. Patients with high levels of NPSR1-AS1 expression were shown to have a shorter disease-specific survival (DSS) or overall survival (OS) than those with low levels of NPSR1-AS1 expression, according to the findings of a clinical investigation. It was determined by multivariate analysis that NPSR1-AS1 expressions served as an independent prognostic factor for the overall survival of LUAD patients. The results of immune cell infiltration revealed that the expressions of NPSR1-AS1 were negatively associated with CD8 T cells, pDC, cytotoxic cells, mast cells, iDC, neutrophils, NK CD56dim cells, DC, Th17 cells, Tgd, and macrophages, while they were positively associated with NK CD56bright cells and B cells. Overall, our findings revealed that NPSR1-AS1 could serve as a potential biomarker to assess the clinical outcome and immune infiltration level in LUAD.
肺腺癌（LUAD）是肺癌最常见的亚型，其发病率持续使肺癌成为全球癌症相关死亡的最大原因。长链非编码RNA（lncRNA）已被证明在肺癌的发生和发展中都起着重要作用。在本研究中，我们旨在探讨lncRNA NPSR1-AS1（NPSR1-AS1）在LUAD中的临床意义及潜在机制。首先，我们对TCGA进行了分析，鉴定出229个差异表达的lncRNA（DELs）（包括216个上调的lncRNA和13个下调的lncRNA）。然后，我们对与生存相关的lncRNA进行了筛选，共发现382个与生存相关的lncRNA。鉴定出15个与生存相关的DELs。其中，我们将注意力集中在NPSR1-AS1上。我们发现，与非肿瘤组织相比，NPSR1-AS1在LUAD标本中的表达要高得多。根据ROC分析结果，NPSR1-AS1高表达对LUAD的AUC值为0.904，95%置信区间为0.881至0.927。一项泛癌研究结果显示，NPSR1-AS1在多种癌症中的表达均显著升高。功能富集分析证实，NPSR1-AS1通过调节多种肿瘤相关途径参与LUAD进展。一项临床研究结果显示，NPSR1-AS1表达水平高的患者比NPSR1-AS1表达水平低的患者具有更短的疾病特异性生存（DSS）或总生存（OS）。多变量分析确定，NPSR1-AS1表达是LUAD患者总生存的独立预后因素。免疫细胞浸润结果显示，NPSR1-AS1的表达与CD8 T细胞、浆细胞样树突状细胞（pDC）、细胞毒性细胞、肥大细胞、未成熟树突状细胞（iDC）、中性粒细胞、自然杀伤CD56dim细胞、树突状细胞（DC）、辅助性T细胞17（Th17）细胞、γδT细胞（Tgd）和巨噬细胞呈负相关，而与自然杀伤CD56bright细胞和B细胞呈正相关。总体而言，我们的研究结果表明，NPSR1-AS1可作为评估LUAD临床结局和免疫浸润水平的潜在生物标志物。
